Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Regeneus Ltd. ( (AU:CMB) ) has shared an update.
Cambium Bio shareholders have strongly backed all resolutions put to an extraordinary general meeting, with each motion passed by poll. The approvals included the issue of placement shares to Zheng Yang Biomedical Technology and authority to issue up to A$10 million worth of new shares, reinforcing the company’s capital-raising capacity to advance its regenerative medicine programs.
The decisive support, with near-unanimous votes in favour, strengthens Cambium Bio’s funding flexibility as it progresses clinical development of its ophthalmology and tissue repair assets. This outcome is likely to bolster the company’s ability to secure strategic partnerships and maintain momentum in bringing its novel biologic therapies toward commercialisation.
The most recent analyst rating on (AU:CMB) stock is a Hold with a A$0.46 price target. To see the full list of analyst forecasts on Regeneus Ltd. stock, see the AU:CMB Stock Forecast page.
More about Regeneus Ltd.
Cambium Bio Limited is a Sydney-based, clinical-stage regenerative medicine company developing innovative biologics for ophthalmology and tissue repair. Its proprietary human platelet lysate technology underpins a pipeline that includes lead dry eye candidate Elate Ocular and the Progenza stem cell platform targeting knee osteoarthritis and other tissue repair indications.
Average Trading Volume: 11,160
Technical Sentiment Signal: Sell
Current Market Cap: A$11.02M
Find detailed analytics on CMB stock on TipRanks’ Stock Analysis page.